Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep-Oct;35(5):2981-2990.
doi: 10.21873/invivo.12593.

Administration of Nivolumab in Metastatic Renal Cell Cancer Following Treatment With mTOR Inhibitors

Jindrich Kopecky  1 , Ondrej Kubecek  2 , Tomas Buchler  3 , Bohuslav Melichar  2   4 , Alexandr Poprach  5   6 , Milada Zemanova  7 , Jana Katolicka  8 , Igor Kiss  5   6 , Jaroslav Hajek  9 , Hana Studentova  4 , Martina Spisarova  4
Affiliations

Administration of Nivolumab in Metastatic Renal Cell Cancer Following Treatment With mTOR Inhibitors

Jindrich Kopecky et al. In Vivo. 2021 Sep-Oct.

Abstract

Background/aim: Immunotherapy with checkpoint inhibitors is currently considered a cornerstone of metastatic renal clear cell cancer (mRCC) therapy. Despite the general improvement in the survival of patients with mRCC, there are some clinical situations that have not been specifically evaluated in clinical trials, such as the use of everolimus before nivolumab.

Patients and methods: We performed a retrospective analysis evaluating the efficacy of nivolumab in the real-world setting, including a subset of patients with previous mTOR inhibitor therapy.

Results: From a total of 56 patients, 25 were pre-treated with everolimus before receiving nivolumab. The overall progression-free survival (PFS), overall survival (OS), and objective response rate were 10.3, 21.3 months, and 34%, respectively. There were no statistically significant differences in patients who were or were not pre-treated with everolimus.

Conclusion: mRCC patients should be treated with checkpoint inhibitors and prior use of mTOR inhibitors should not be a definitive exclusion criterium.

Keywords: Renal cell cancer; mTOR inhibitor; neutrophil-lymphocyte ratio; nivolumab; platelet-lymphocyte ratio; systematic inflammation index.

PubMed Disclaimer

Conflict of interest statement

JK, JKa, AP and HS received honoraria and travel grants from Novartis, Pfizer, Roche, Bristol Myers Squibb, and Ipsen. BM, TB, MZ and IK received honoraria and research support from Novartis, Pfizer, Roche, Bristol Myers Squibb, and Ipsen. OK, JH and MS declare no conflicts of interest in relation to this study.

Figures

Figure 1
Figure 1. Survival analysis using the Kaplan-Meier method for all patients: (A) Progression-free survival; (B) Overall survival.
Figure 2
Figure 2. Swimmer plot for patients with complete response (CR), partial response (PR), and stable disease (SD). DOR: Duration of response.
Figure 3
Figure 3. Survival analysis for patients with and without previous everolimus treatment: (A) Progression-free survival; (B) Overall survival.
See this image and copyright information in PMC

References

    1. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, Donskov F, Bono P, Wagstaff J, Gauler TC, Ueda T, Tomita Y, Schutz FA, Kollmannsberger C, Larkin J, Ravaud A, Simon JS, Xu LA, Waxman IM, Sharma P, CheckMate 025 Investigators Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803–1813. doi: 10.1056/NEJMoa1510665. - DOI - PMC - PubMed
    1. Heng DY, Xie W, Regan MM, Harshman LC, Bjarnason GA, Vaishampayan UN, Mackenzie M, Wood L, Donskov F, Tan MH, Rha SY, Agarwal N, Kollmannsberger C, Rini BI, Choueiri TK. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol. 2013;14(2):141–148. doi: 10.1016/S1470-2045(12)70559-4. - DOI - PMC - PubMed
    1. Teishima J, Inoue S, Hayashi T, Mita K, Hasegawa Y, Kato M, Kajiwara M, Shigeta M, Maruyama S, Moriyama H, Fujiwara S, Matsubara A. Impact of the systemic immune-inflammation index for the prediction of prognosis and modification of the risk model in patients with metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitors. Can Urol Assoc J. 2020;14(11):E582–E587. doi: 10.5489/cuaj.6413. - DOI - PMC - PubMed
    1. Zhong JH, Huang DH, Chen ZY. Prognostic role of systemic immune-inflammation index in solid tumors: a systematic review and meta-analysis. Oncotarget. 2017;8(43):75381–75388. doi: 10.18632/oncotarget.18856. - DOI - PMC - PubMed
    1. Hu K, Lou L, Ye J, Zhang S. Prognostic role of the neutrophil-lymphocyte ratio in renal cell carcinoma: a meta-analysis. BMJ Open. 2015;5(4):e006404. doi: 10.1136/bmjopen-2014-006404. - DOI - PMC - PubMed